Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.
Summary
This bill would require New York health insurance carriers and health plans to cover at least one abuse-deterrent opioid analgesic drug product for each opioid active ingredient on their formularies or drug lists. It also limits patient cost-sharing for these products so that it cannot be higher than the lowest cost-sharing tier applied to comparable non-abuse-deterrent opioid drugs, whether the product is brand-name or generic. The bill further prohibits insurers from using higher cost-sharing, prescribing disincentives, or similar mechanisms to satisfy the coverage requirement.
The measure also restricts utilization management practices. Prior authorization and other review or denial processes for opioid analgesics cannot require a patient to first use a non-abuse-deterrent opioid in order to access an abuse-deterrent version. The bill defines key terms such as opioid analgesic drug product, abuse-deterrent opioid analgesic drug product, and cost-sharing, and it would apply to policies and contracts issued, renewed, modified, altered, or amended 120 days after enactment.
Impact
If enacted, the bill would amend the New York Insurance Law by adding a new section requiring coverage and access protections for FDA-approved abuse-deterrent opioid medications. It would affect health insurers, health plans, prescribers, pharmacists, and patients by changing formulary design, cost-sharing rules, and prior authorization practices for opioid analgesics. The practical effect would be to make abuse-deterrent opioid options more available and financially comparable to non-abuse-deterrent opioids in covered plans.
Sentiment
The bill’s stated purpose and caption indicate strong support for measures aimed at reducing opioid abuse and diversion through patient access to abuse-deterrent technology. Based on the text alone, the proposal is framed as a public health and consumer access measure rather than a restriction on treatment. No committee transcript or vote data were provided, so there is no recorded legislative debate or formal vote history to indicate broader support or opposition.
Contention
The main likely point of contention is the mandate on insurers and health plans to cover abuse-deterrent opioid products and to limit cost-sharing, which could raise concerns about premium impact, formulary flexibility, and insurer utilization management authority. Another possible issue is whether requiring access to abuse-deterrent formulations meaningfully reduces misuse enough to justify the coverage mandate. Patients, advocates for pain management, insurers, and pharmacy benefit managers would be the primary stakeholders affected by these provisions.